Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Home infusion for myeloma drug passes early safety check

NCT ID NCT05041933

Disease control Sponsor: University Hospital, Limoges Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested whether the multiple myeloma drug carfilzomib can be safely given at home instead of in a hospital. Seventeen patients received their first cycle in the clinic and later cycles at home, with nurses administering the short infusion. The main goal was to see if the process followed safety rules without errors. If it works, this model could make treatment more convenient for patients and reduce hospital burden.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
carfilzomib (a chemotherapy drug given as a short intravenous infusion)
What this could lead to
If successful, this could show that giving certain chemotherapy infusions at home is safe and practical, potentially improving patient quality of life and reducing hospital visits.
What could go wrong
This is a very small pilot study (17 people) that only looked at whether the process works without errors. It does not test if the drug itself is effective or safe, and results may not apply to other drugs or regions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

17 people

The number who actually took part.

Started

Sep 2021

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient with relapsed or refractory multiple myeloma (having received at least one previous treatment),

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects aged 18 years or over. * Eligible for care by one of the four HAH structures in accordance with HAS criteria, * With relapsed or refractory multiple myeloma (having received at least one previous treatment), * Whose case has been examined at multidisciplinary team (MDT) meetings at Limoges University Hospital Centre, * Receiving carfilzomib parenteral chemotherapy outsourced to an HAH setting (all patients receive the entire first cycle of carfilzomib and the 1st day of each of the subsequent cycles in an outpatient clinic). * Having read the information leaflet concerning the Carfil-HAD study, * Not objecting to the use of their data in the context of this study. Exclusion Criteria: * Inability to understand the protocol or complete the questionnaires. * Refusing to complete the questionnaires.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematological diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematologic disorder plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematological diseases

Contacts and locations

Locations

  • Limoges Hospital

    Limoges, 87 042, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.